Ribometrix completed a $30 million Series A financing in late 2018 and is headquartered in Durham, North Carolina.

In 2019, Ribometrix entered into a strategic collaboration with Vertex Pharmaceuticals to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases.

The company also entered into strategic collaboration with Genentech, a member of the Roche Group, in early 2021 to discover and develop novel RNA-targeted small molecule therapeutics against several targets.